NCT02066454已完成3 期
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
University Hospital, Grenoble19 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2014年6月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 108
- 试验地点
- 19
- 主要终点
- Total VTE and VTE-related death. Major and clinically relevant non major bleeding - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis
研究概览
简要总结
To evaluate:
- the incidence of venous thromboembolic event (VTE)
- the incidence of hemorrhagic complications, In a population of patients with myeloma who are treated with IMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day
详细描述
MYELAXAT trial is multicentre, open trial which aims to evaluate the incidence of venous thromboembolic event (VTE) and the incidence of hemorrhagic complications. All patients with Myeloma treated with iMiDs and require thromboprophylaxis for 6 months, using an oral anti-Xa anticoagulant, Apixaban, in a preventive scheme, 2.5 mg x2/day
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients (men/women) aged more than 18 years
- •All consecutive patients, with myeloma, in first-line treatment or in relapse, who are treated - With IMiDs (MPT, Melphalan -Prednisone -Thalidomide ; Lenalidomide - Dexamethasone).
- •who require prevention of venous thromboembolic events with Aspirin or Low molecular Weight Heparin (LMWH) for a minimum duration of 6 months At least, 2/3 of patients will be treated with Lenalidomide-Dexamethasone.
- •Written informed consent
- •Patients affiliated to the French social security system or equivalent
排除标准
- •Patient who needs curative anticoagulant treatment (heparin, LMWH, vitamin K antagonists, Dabigatran, Rivaroxaban, Apixaban) for an associated disorder (mechanical valve, atrial fibrillation or venous thromboembolic disease in the previous 6 months).
- •Patient who needs preventive treatment with an anticoagulant in a post-operative context
- •Patient who needs anti-platelet treatment (Aspirin, Clopidogrel, Prasugrel, Ticagrelor or dual anti-platelet therapy )
- •Patient with active bleeding or at a high risk of bleeding (ulcer disease, intracranial bleeding in the previous 6 months, uncontrolled hypertension)
- •Patient having undergone a surgical intervention within the past 30 days likely to expose them to an haemorrhagic risk
- •Active hepatic disease (hepatitis, cirrhosis)
- •Severe renal insufficiency (creatinine clearance using the Cockcroft equation < 30 ml/mn)
- •Known allergic reaction to Apixaban
- •Contraindication to the use of an anticoagulant treatment
- •Prohibited concomitant treatment
- •inhibitors of CYP3A4 and P-gp : azole antimycotic agents (ketoconazole, itraconazole, voriconazole, posaconazole), inhibitors of HIV protease (ritonavir, indinavir, nelfinavir, atazanavir, saquinavir), specific macrolide antibiotics (clarithromycine, telithromycine)
- •other antithrombotic treatment : salicylate derivates (aspirin, products containing aspirin), antiplatelet therapy, heparin (unfractionated heparin, low molecular weight heparin, danaparoide sodique, fondaparinux), hirudines, oral anticoagulants (vitamin K antagonists, rivaroxaban, dabigatran)
- •Patient with AST or ALT rate > 3 times upper limit of normal
- •Patient with Bilirubin rate > 1.5 times upper limit of normal
- •Patient with Platelets rate < 75 G/l
- •Patient with Creatinine Clearance (Cockcroft) < 30 ml/mn
- •Incidental finding of a proximal Deep Venous Thrombosis on the screening ultrasound
- •Patients refusing or unable to give a written consent of information
- •Patient unable to comply with the protocol requirement, in the investigator's opinion
- •Life expectancy less than 6 months
- •Incarcerated patients
- •Pregnancy or possibility of pregnancy within 6 months
- •Females of childbearing potential without reliable contraception
- •Ecog > 2
研究组 & 干预措施
Apixaban
Experimental
oral direct anti-Xa anticoagulant
干预措施: Apixaban (Drug)
结局指标
主要结局
Total VTE and VTE-related death. Major and clinically relevant non major bleeding - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis
时间窗: 7 months
Total VTE (fatal or non fatal pulmonary embolism, symptomatic distal or proximal DVT of lower limbs, and asymptomatic proximal DVT detected by bilateral compression ultrasound) and VTE-related death. - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis
次要结局
- incidence of major and clinically relevant non major bleeding(7 months)
- incidence of arterial cardiovascular events(7 months)
- incidence of venous thromboembolic complications(7 months)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
4 期
DOACs for Stroke Prevention Post Ventricular Tachycardia AblationPremature Ventricular ContractionStrokeVentricular TachycardiaNCT02666742Kansas City Heart Rhythm Institute246
招募中
不适用
Thrombophilia Assessment Under DOAC: Effectiveness of Activated CharcoalThrombophiliaNCT06171984University Hospital, Strasbourg, France200
进行中（未招募）
1 期
Evaluation of the use of an oral direct anti-Xa anticoagulant, Apixaban in prevention of venous thromboembolic disease in patients treated with IMiDs during myeloma: a pilot studyMultiple myelomaEUCTR2013-003190-99-FRCHU de Grenoble
已完成
4 期
Prophylaxis of Deep Vein Thrombosis Following Total Hip ArthroplastyOsteoarthritis, HipFemur Head NecrosisFemoral Neck FracturesNCT02379663Samsung Medical Center639
已完成
不适用
Direct Oral Anticoagulants and Venous ThromboembolismMajor BleedVenous ThromboembolismNCT02833987Canadian Network for Observational Drug Effect Studies, CNODES59,525